Optimizing the management of transthyretin familial amyloid polyneuropathy in Europe: early diagnosis and effective care
نویسنده
چکیده
Transthyretin familial amyloid polyneuropathy (TTR-FAP) is an autosomal dominant disorder caused by the extracellular deposition of insoluble amyloid fibrils in the endoneurium. TTR-FAP occurs as a result of transthyretin (TTR) gene mutation, and more than 100 TTR mutation types are recognized [1]. It is a highly disabling and life-threatening disease, characterized by progressive sensorimotor and autonomic neuropathy, and is fatal within 7–12 years of disease onset [2]. For some time, it was believed that TTR-FAP was an endemic disease in Europe, affecting only north Portugal, Sweden, Cyprus, and Majorca; however, with improvements in diagnostic methods in recent years, numerous sporadic cases have been diagnosed in many other countries [1]. This supplement arose from discussions that took place during two meetings (November 2012 and March 2014) of an emerging group that is provisionally called the European Network for TTR-FAP (ATTReuNET). The group currently includes a representative panel of 15 TTR-FAP experts from 10 European countries (Bulgaria, Cyprus, France, Germany, Italy, the Netherlands, Portugal, Spain, Sweden, and Turkey), including nine National Reference Centres for familial amyloid polyneuropathy. As an emergent network, ATTReuNET is open to collaborations with other expert centres in Europe. The group members devised and completed a semistructured questionnaire on the situation of TTR-FAP in their countries prior to the 2012 meeting and updated the responses in 2014. This information was used to guide the live discussion, with a focus on five main areas: epidemiology and local structure of care; diagnosis; management and funding; follow-up care of both patients and asymptomatic carriers; and the overall patient experience. This supplement contains three articles that aim to disseminate the major findings from these meetings and to align these findings with data available from a systematic review of the published
منابع مشابه
First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
PURPOSE OF REVIEW Early and accurate diagnosis of transthyretin familial amyloid polyneuropathy (TTR-FAP) represents one of the major challenges faced by physicians when caring for patients with idiopathic progressive neuropathy. There is little consensus in diagnostic and management approaches across Europe. RECENT FINDINGS The low prevalence of TTR-FAP across Europe and the high variation i...
متن کاملSixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP
PURPOSE OF REVIEW Transthyretin familial amyloid polyneuropathy (TTR-FAP) is a highly disabling, life-threatening disease characterized by progressive sensorimotor and autonomic neuropathy. The profile of the disease across Europe is inadequately understood at present. RECENT FINDINGS The incidence and clinical presentation of TTR-FAP varies widely within Europe, with early and late-onset dis...
متن کاملFamilial Amyloid Polyneuropathy Type IV (FINNISH) with Rapid Clinical Progression in an Iranian Woman: A Case Report
Familial amyloid polyneuropathy (FAP) type IV (FINNISH) is a rare clinical entity with challenging neuropathy and cosmetic deficits. Amyloidosis can affect peripheral sensory, motor, or autonomic nerves. Nerve lesions are induced by deposits of amyloid fibrils and treatment approaches for neuropathy are challenging. Involvement of cranial nerves and atrophy in facial muscles is a real concern i...
متن کاملRecommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis
PURPOSE OF REVIEW These recommendations highlight recent experience in genetic counselling for the severe autosomal-dominant, late-onset transthyretin familial amyloid polyneuropathy (TTR-FAP) disease, and present a structured approach towards identification and monitoring of asymptomatic carriers of the mutated gene. RECENT FINDINGS The effectiveness of current treatment options is still lim...
متن کاملEpidemiology of transthyretin familial amyloid polyneuropathy in Portugal
Background Transthyretin Familial Amyloid Polyneuropathy (TTRFAP) is a rare, progressive, debilitating and life-threatening neurodegenerative disease. TTR-FAP is a rare disease worldwide. In Europe a disease is defined as rare when it affects less than 1 in 2000 inhabitants. Portugal has the largest cluster worldwide nonetheless recent Portuguese epidemiologic data is lacking. The purpose of th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 29 شماره
صفحات -
تاریخ انتشار 2016